NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Clearly not an oversight. I remember someone stating DI said the price rise from the 2020 endpoint change overseas was a premature spike, or something to that effect. “Spilled the beans” was another comment attributed to him, I believe. I have the same question. If the impact of changing endpoints early on was not adverse, why did NWBO wait to then change the U.S. endpoints until after topline instead of, say, a year earlier. It’s not like they could go back from the change anyway, why not get it out there, since it already was overseas. It would have been positively received had it been done much earlier on.